Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis

SpringerPlus

Table 5 Changes in eGFR by year for various treatment options (variation per year compared with previous year)

Treatment	Year 1	Year 2	Year 3	Year 4	Year 5	Source	Year >5
TDF	−6.40	0.70	0.70	0.70	0.70	Tsai et al. (2016)	−0.72
LDT	9.57	5.86	10.81	10.81	10.81	Qi et al. (2015)	9.57
ETV	0.00	1.99	−3.27	−3.27	−3.27	Qi et al. (2015)	−1.57
LAM	−4.72	−5.40	−2.29	−2.29	−2.29	Qi et al. (2015)	−3.40
ADV	−6.92	−4.72	−3.74	−3.74	−3.74	Qi et al. (2015)	−4.57
LDT + ADV	9.57	5.86	10.81	10.81	10.81	Assumed to be same as LDT	9.57
LDT + TDF	9.57	5.86	10.81	10.81	10.81	Assumed to be same as LDT	9.57
BSC	−0.69	−0.38	−0.73	−0.73	−0.73	Qi et al. (2015)	−0.65

eGFR was measured in mL/min/1.73 m². For the eGFR changes, for each treatment, the last available observations were carried forward till year 5
ADV adefovir dipivoxil, BSC best supportive care, eGFR estimated glomerular filtration rate, ETV entecavir, LAM lamivudine, LDT telbivudine, TDF tenofovir